title: Transmitted antiretroviral drug resistance in the men who have sex with men HIV patient cohort, Beijing, China, 2008-2011.
abstract: Transmitted drug resistance (TDR) is an ongoing public health problem in HIV disease treatment. However, little is known about TDR among men who have sex with men (MSM) patients in China. In addition, TDR prevalence among patients with acute HIV infection (AHI) or early HIV infection (EHI) was believed higher than that of patients with chronic HIV infection (CHI), but as AHI is typically either unidentified or crudely defined in large populations, very few direct comparisons have been made. We did a retrospective analysis of TDR in 536 antiretroviral-naive MSM patients from our immunodeficiency clinics at You'an Hospital, Capital Medical University (CMU), in Beijing, China, 2008-2011. The cohort included 266 patients with AHI/EHI and 270 patients with CHI. We analyzed the subtype, estimated the TDR prevalence, and characterized the model of TDR and the predicted drug sensitivity. Additionally, we made a comparison of TDR between the patients with AHI/EHI and patients with CHI. Our results indicated that among the 536 patients, HIV-1 subtype CRF01_AE accounted for 52.1%, subtype B accounted for 24.8%, CRF07_BC/ CRF08_BC accounted for 21.6% (116/536), and 1.3% were denoted as unique recombinant forms (URFs). A total of 7.8% patients had one or more transmitted HIV-1 drug resistance mutations, representing 6.2% for PI-related mutations, 0.9% for NRTI-related mutations, and 1.7% for NNRTI-related mutations. Although patients with AHI/EHI had a higher TDR prevalence as compared to that of patients with CHI, the difference was not statistically significant. There was no significant difference in TDR model and predicted drug susceptibility between the two groups of patients either. This study provides important strategic information for public health planning by healthcare officials in China and warrants a comprehensive study with larger patient cohorts from various healthcare centers within China.
authors.affiliation: 1 Center for Infectious Diseases, Beijing You'an Hospital, Capital Medical University , Beijing, China .
authors.forename: Lili
authors.initials: L
authors.lastname: Dai
authors.forename: Ning
authors.initials: N
authors.lastname: Li
authors.forename: Feili
authors.initials: F
authors.lastname: Wei
authors.forename: Jingyun
authors.initials: J
authors.lastname: Li
authors.forename: Yongjian
authors.initials: Y
authors.lastname: Liu
authors.forename: Wei
authors.initials: W
authors.lastname: Xia
authors.forename: Tong
authors.initials: T
authors.lastname: Zhang
authors.forename: Caiping
authors.initials: C
authors.lastname: Guo
authors.forename: Wen
authors.initials: W
authors.lastname: Wang
authors.forename: Stanley A
authors.initials: SA
authors.lastname: Schwartz
authors.forename: Supriya D
authors.initials: SD
authors.lastname: Mahajan
authors.forename: Chiu-Bin
authors.initials: CB
authors.lastname: Hsiao
authors.forename: Hao
authors.initials: H
authors.lastname: Wu
mesh_terms: D000293:Adolescent; D000328:Adult; D044966:Anti-Retroviral Agents / Q000494:pharmacology*; D002681:China / Q000453:epidemiology; D015331:Cohort Studies; D024882:Drug Resistance, Viral; D005838:Genotype; D015658:HIV Infections / Q000453:epidemiology* / Q000635:transmission / Q000821:virology*; D015497:HIV-1 / Q000145:classification / Q000187:drug effects* / Q000235:genetics / Q000302:isolation & purification; D018451:Homosexuality, Male; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D009154:Mutation; D015995:Prevalence; D012189:Retrospective Studies; D055815:Young Adult
chemical_list: D044966:Anti-Retroviral Agents
references.citation: AIDS Res Hum Retroviruses. 2013 Mar;29(3):633-7
references.pmid: 23121221
references.citation: J Infect Dis. 2011 Apr 15;203(8):1174-81
references.pmid: 21451005
references.citation: PLoS One. 2009;4(3):e4724
references.pmid: 19266092
references.citation: J Antimicrob Chemother. 2011 Jul;66(7):1467-80
references.pmid: 21502281
references.citation: AIDS Rev. 2012 Jan-Mar;14(1):17-27
references.pmid: 22297501
references.citation: PLoS One. 2010 Dec 10;5(12):e15510
references.pmid: 21170322
references.citation: J Acquir Immune Defic Syndr. 2012 Dec 1;61(4):448-54
references.pmid: 23143525
references.citation: J Acquir Immune Defic Syndr. 2012 Oct 1;61(2):258-62
references.pmid: 22692092
references.citation: J Acquir Immune Defic Syndr. 2010 Apr;53(5):633-9
references.pmid: 21080527
references.citation: AIDS. 2010 May 15;24(8):1203-12
references.pmid: 20395786
references.citation: AIDS Res Hum Retroviruses. 2012 Dec;28(12):1723-8
references.pmid: 22587343
references.citation: Public Health. 2011 May;125(5):260-5
references.pmid: 21658537
references.citation: Clin Infect Dis. 2012 May;54 Suppl 4:S320-3
references.pmid: 22544196
references.citation: AIDS Res Hum Retroviruses. 2011 Oct;27(10):1047-53
references.pmid: 21417755
references.citation: Proc Natl Acad Sci U S A. 2008 Oct 28;105(43):16725-30
references.pmid: 18936487
references.citation: Antivir Ther. 2009;14(5):673-8
references.pmid: 19704170
references.citation: Clin Infect Dis. 2013 Jun;56(11):1667-74
references.pmid: 23446628